Ann: 1H FY25 Results Investor Briefing Invitation, page-2

please team, do not ask fluffy questions or those that an elicit a broad, no info, answer

something like: how many people do you have enrolled in the BARDA trial (we would like to know)

also, the cash flow last Q was minus 3.7 mill; we are 2/3rd through this q, will the cash flow outflow, improve back to the more common 2.5 mill

also, you said you were helping institutions in the the USA using FebriDx overcome the delay in the insurance companies refunding $42 per use; do you have any update on that task

also, have you applied in Australia to have FebriDx on the medical rebate scheme

also, (this is open ended) do you feel there is a real care in govts and medical industry re AMR; it seems nothing is being done to combat it, other than talking about it